Contributions of the tumor microenvironment (TME) to progression in thyroid cancer are largely unexplored and may illuminate a basis for understanding rarer aggressive cases of this disease. In this study, we investigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specific expression of oncogenic BRAF and loss of Pten (Braf V600E /Pten À/À /TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC). We found that fibroblasts were recruited to the TME of Braf In clinical specimens, we found COL1A1 and LOX to be upregulated in PTC and expressed at highest levels in PDTC and anaplastic thyroid cancer. Additionally, increased expression levels of COL1A1 and LOX were associated with decreased survival in thyroid cancer patients. Overall, our results identified fibroblast recruitment and remodeling of the extracellular matrix as pivotal features of the TME in promoting thyroid cancer progression, illuminating candidate therapeutic targets and biomarkers in advanced forms of this malignancy. Cancer Res; 76(7); 1804-13. Ó2016 AACR.
Introduction
Thyroid cancer is the most common endocrine malignancy and is predicted to be the fourth most commonly diagnosed cancer by 2030 (1) . The BRAF V600E mutation is the most common genetic alteration in thyroid cancer, in particular papillary thyroid cancer (PTC), and is associated with more aggressive disease (2) . Poorly differentiated (PDTC) and anaplastic thyroid cancers (ATC) often have mutations in BRAF as well as mutations that result in constitutive PI3K signaling, and are often unresponsive to treatments for thyroid cancer, including radiation and chemotherapy (3) (4) (5) . Additionally, the success of targeted inhibition strategies for advanced thyroid cancers has been limited (6, 7) . The increasing incidences of thyroid cancer, coupled with our relative lack of understanding of drivers of disease progression, underscore the need for novel therapeutics as well as identification of biomarkers that are predictive of aggressive disease.
The tumor microenvironment (TME) is comprised of multiple cellular and non-cellular components, including extracellular matrix (ECM) proteins, that converge to promote tumorigenesis in a variety of solid malignancies (8, 9) . Tumor cells induce the migration of non-malignant cells, such as fibroblasts, endothelial cells, and immune cells, to the TME through direct cell-cell contact and indirect mechanisms, which collectively support the development of a primary tumor niche (10) . The influence of tumor-stromal cross-talk on tumor progression is recognized in many different types of cancer. However, the mechanisms by which tumor cells establish a permissive niche that promotes thyroid cancer progression remain largely undefined.
Cancer-associated fibroblasts (CAF) represent a heterogeneous population of fibroblasts that are recruited and activated to augment tumor progression in many different solid tumors (11) (12) (13) . In addition to stimulating tumor cell proliferation, angiogenesis, invasion, and metastasis, CAFs also drive tumorigenesis by upregulating the production of ECM components, including type 1 collagen (Col 1) and ECM modifying enzymes (14) (15) (16) . Col 1 is the most abundant ECM scaffolding protein and its increased deposition in the TME is associated with tumor progression (17) (18) (19) , increased incidence of metastasis (20) and drug resistance (21) in human cancers. These observations are supported by in vivo and in vitro studies demonstrating that Col 1 promotes the migration, invasion, and metastasis of tumor cells (22) (23) (24) .
A thorough understanding of the role of tumor derived signals in establishing an environment conducive to tumor development and the effects of stromal derived signals on tumor cell behavior in thyroid cancer is largely unexplored. To identify potential mechanisms of thyroid cancer progression in the context of the TME, a novel model of thyroid cancer progression (Braf V600E /Pten À/À /TPO-Cre) was created and the TME dissected to identify factors that influence thyroid tumorigenesis. Braf activation and Pten loss cooperate in PTC development that rapidly progresses to PDTC characterized by a fibrotic and reactive tumor stroma enriched with CAFs, fibrillar collagen deposits, and increased expression of lysyl oxidase (Lox), an ECM modifying enzyme that catalyzes collagen fiber crosslinking. We extended these findings to human disease and found that increased COL 1 and LOX expression is associated with more aggressive well-differentiated thyroid cancer subtypes, PDTCs, and a poorer overall survival rate. Based on these observations, we propose that a regulatory loop exists between thyroid tumor cells, CAFs, collagen, and Lox, which potentiates thyroid cancer progression. These components may serve as therapeutic targets for advanced thyroid cancers, and future studies will investigate therapeutic strategies targeting the TME and ECM in our in vivo models.
Materials and Methods

Experimental animals
All animal experiments were performed at the University of Arkansas for Medical Sciences and approved by the Institutional Animal Care and Use Committee. The LSL-Braf V600E ,Pten
, and thyroid peroxidase promoter (TPO)-Cre strains have been previously described (25, 26) . Mice were on mixed C57BL6/129SVJ genetic backgrounds. Genotypes were determined by PCR as previously described (25, 26) .
Histology and immunohistochemistry
Thyroid tissues were fixed in 10% formalin-buffered acetate and embedded in paraffin. Five-micrometer sections were prepared, and histological diagnosis was performed by a thyroid pathologist (N. Massoll). For further details, see Supplementary Materials and Methods.
Cell lines
The Braf, B297T, and B1180T cell lines were established from Braf Cre thyroid tumors, detailed in Supplementary Materials and Methods. Cell lines were authenticated using short tandem repeat (STR) DNA profiling (DDC Medical). Independent murine mammary CAF lines (mCAF and 4F) were isolated from MMTV-PyVmT model as previously described (27) .
RT-PCR analysis
Total RNA was extracted using the RNeasy Plus Mini Kit (Qiagen). Equal amounts of RNA template were reverse transcribed using the Verso cDNA synthesis kit (Thermo Scientific). Differential mRNA expression of type 1 collagen (Col1a1), lysyl oxidase (Lox) and 18s was measured using TaqMan Mastermix and predesigned Taqman assays (Applied Biosystems). Four microliters of cDNA from tumor samples and independent passages of each cell line were run in triplicate on a Bio-Rad CFX96. Q-Gene software (28) was used to determine relative normalized expression to 18s. Data analysis was based on the C t method.
Migration assays
Migration assays were performed in 24-well plates with Fluoroblok inserts (Falcon). Forty thousand mCAF or 4F fibroblasts were seeded on each Fluoroblok insert in 0.5%FBS/F12. Conditioned media from tumor lines were added to the bottom chamber of the Fluoroblok plate. Eight hours after incubation at 37 C, cells on the Fluoroblok inserts were stained with 2 mmol/L Calcein AM (Life Technologies). Fluorescent values were obtained at a wavelength of 485 ex/520 em on a Synergy H1 multimode reader (BioTek) to quantitate migration. The optics position of the plate reader was set to read from the bottom of the plate in order to only image cells that had migrated through the transwell. Images were taken on the EVOS FL imaging system.
Proliferation assays
Proliferation assays were performed in 96-well plates. One thousand fibroblasts were seeded in quadruplicate per treatment condition in complete media for attachment. Following overnight attachment, the media were replaced with medium containing 0.5% FBS, 10% FBS, or conditioned media from tumor cell lines. Proliferation was assessed using the CellTiter-Glo luminescent cell viability assay (Promega). One well per treatment was incubated with a 1 mmol/L Calcein AM for 30 minutes at 37 C and imaged using an EVOS FL imaging system.
Live-cell microscopy
Tumor cells were plated in 35-mm cell culture dishes either tissue culture treated or coated with 100 mg/mL rat tail collagen I (Sigma). Following attachment in complete medium, cells were serum starved overnight, then stimulated with 10% FBS and immediately imaged under phase contrast on an Axiovert 100 M microscope fitted with a Zeiss Axiocam ICM1 camera and maintained at 37 C and 5% CO 2 using a Live Cell Pathology incubator. Images were collected every minute for 4 hours. The images were analyzed using NIH ImageJ software (Version 1.50e) with the MTrackJ Plugin to determine distanced travelled by cells. The center of each cell nucleus was used as the point of tracking, and cells undergoing mitosis were excluded from analysis. Track length was measured for 10 individual cells per treatment and repeated at least thrice.
Human thyroid cancer database analysis
The Oncomine platform (www.oncomine.org; ref. (31, 32) , was used to obtain summary statistics on co-occurrence of genomic alterations in BRAF, NRAS, HRAS, KRAS, COL1A1, and LOX in thyroid carcinomas in 397 thyroid cancer cases. Odds ratios to indicate the likelihood of mutual exclusivity or co-occurrence of each pair of genes were calculated. P values were determined by the Fisher exact test.
Statistical analysis
All data were analyzed using Prism 6 software (GraphPad). Differences with P values of 0.05 were considered statistically significant.
Results
Braf
V600E and PI3K signaling cooperate in the development of PTCs that rapidly progress to PDTC in vivo MAPK signaling plays a critical role in thyroid cancer initiation, as evidenced by our previous studies demonstrating that endogenous expression of Braf V600E is sufficient to induce murine PTCs that recapitulate human disease (25) . BRAF mutations are associated with more aggressive PTC and are often found in conjunction with mutations that result in constitutive PI3K/AKT signaling, including PIK3CA and PTEN mutations, in PDTCs (33) . This led to the hypothesis that simultaneous MAPK activation via Braf V600E and PI3K activation via Pten loss would cooperate in thyroid cancer initiation and progression to advanced disease. To determine whether Braf V600E and PI3K signaling could cooperate in thyroid cancer progression in vivo, LSL-Braf V600E /Pten flox/flox mice were crossed with Pten flox/flox /TPOCre mice to generate mice in which Braf V600E is conditionally activated and Pten is homozygously inactivated through thyroid-specific Cre recombinase activation (Braf V600E /Pten
/TPO-Cre mice developed PTCs that rapidly progressed to PDTCs with 100% penetrance and lethality by weaning (Fig. 1A) . In stark contrast to wild-type (WT) thyroid glands with normal follicular architecture (Fig. 1B) ,
/TPO-Cre tumors encompass the entire thyroid gland and display many of the classical hallmarks of highgrade human PTC, including formation of papillae, fine chromatin, and nuclear grooves ( /TPO-Cre mice provide a model by which to investigate factors within the TME that may contribute to disease progression.
The TME of Braf /TPO-Cre tumor sections revealed areas of fibrosis along the tumor periphery and cells with fibroblast morphology ( Fig. 2A and B, top, arrows). In contrast, no areas of fibrosis were observed in WT thyroid tissue. These cells were confirmed as fibroblasts via immunostaining with aSMA. In contrast to WT thyroid, in which no aSMA staining was observed, Braf V600E /Pten À/À / TPO-Cre tumors displayed robust peripheral and intratumoral aSMA staining, indicating fibroblast recruitment and infiltration ( Fig. 2A and B /TPO-Cre mice (Braf-1, B1180T, and B297T) and tested the ability of these cell lines to drive the proliferation and migration of two independent CAF lines in vitro (27) . Conditioned media collected from Braf and B297T cells significantly increased mCAF and 4F fibroblast proliferation in comparison with serum free controls after 48 hours of incubation ( Fig. 3A and Supplementary Fig.  S1A ). To determine whether increased proliferation was specific to factors secreted by Braf-driven thyroid tumor cells, the experiments were repeated with the Hras-driven thyroid tumor cell line H340T. Conditioned medium isolated from H340T cells had no effect on the proliferation of mCAF or 4F after 48 hours compared with the serum-free control ( Fig. 3A and Supplementary Fig. S1A ). Additionally, conditioned media from Braf, B1180T, and B297T cells significantly increased the migration of mCAF and 4F fibroblasts in Transwell assays compared with serum-free controls ( /TPO-Cre tumors secrete factors that induce fibroblast migration and likely drives fibroblast recruitment to Braf V600E /Pten À/À /TPO-Cre tumors in vivo. Consistent with the proliferation studies, conditioned media from Hras G12V -driven murine thyroid tumor cell lines did not stimulate mCAF or 4F migration compared with serum-free controls ( Fig. 3B and C; Supplementary Fig. S1B and S1C). Together, these results suggest that Braf, but not Hras, activation results in secretion of tumor-derived factors that induce the proliferation and recruitment of fibroblasts in murine thyroid cancer. TGFb is a key mediator of fibroblast activation during wound healing and exerts promitogenic and chemotactic effects on fibroblasts (reviewed in 12). To determine whether the induction of fibroblast migration and proliferation in response to conditioned medium from Braf-driven tumor cells is TGFb dependent, proliferation and migration experiments were repeated with TGFbRII knockout fibroblasts (27) . Treatment with conditioned medium from Braf, B1180T, B297T, and H340T inhibited the proliferation of TGFbRII knockout fibroblasts compared with 0.5% FBS (Supplementary Fig. S2A ). No migration through transwells was observed in any treatment group, even after 24 hours of exposure to 10% FBS ( Supplementary Fig. S2B ), indicating that intact TGFbRII signaling is required for the migration of fibroblasts. To determine whether Braf-driven tumor cells could induce activation of TGFb signaling in fibroblasts, 4F fibroblasts were treated with conditioned medium from Braf, B1180T, and B297T cells and Western blot analysis for phosphorylated SMAD 2 and 3 performed. Treatment with conditioned medium from Braf-driven thyroid tumor cell lines did not induce the phosphorylation of SMAD 2 or 3 in fibroblasts ( Supplementary Fig. S2C ). Collectively, these data suggest that while TGFb signaling is permissive for the induction of fibroblast migration in response to Braf-driven tumor cell-derived signals, alternative pathways are likely being activated by tumor-derived factors to induce fibroblast proliferation and migration.
Increased total and fibrillar collagen deposition and Lox expression in Braf V600E /Pten hom /TPO-Cre tumors Collagens, in particular collagen 1 (Col 1), are primarily derived from fibroblasts and augment tumor cell invasion and migration in vivo and in vitro (13) (14) (15) (16) (17) (18) (19) (20) . We hypothesized that the recruitment of fibroblasts to Braf (Fig. 4D) . Additionally, Col 1 was undetectable in ECM derived from Braf
V600E
-driven tumor cells in vitro (data not shown). To test the hypothesis that fibroblasts are the predominant source of Col 1 within the TME of Braf The biomechanical properties and deposition of ECM proteins are altered during tumorigenesis. Further, the activity of tumor and stromal derived matrix metalloproteinases (MMP) and collagen-cross-linking enzymes, which modulate the structural stability of ECM proteins, is increased in different cancers (37) . Lysyl oxidase (Lox) is an ECM-modifying enzyme that catalyzes the cross-linking of collagen fibers, resulting in increased collagen fiber stability and ECM stiffness, which can enhance the invasive capacity of tumor cells in vivo (38) . Upregulation of LOX is observed in a variety of solid tumors (39) (40) (41) and correlates with reduced metastasis-free survival in breast and head and neck cancers (39) . LOX has recently been found to be upregulated in thyroid cancer and potentiates metastasis and invasion of anaplastic thyroid cancer cell lines in vivo (40) . Lox expression was significantly upregulated in Braf V600E /Pten À/À /TPO-Cre tumors compared with WT thyroid controls (Fig. 4C) . Lox expression was also increased in B1180T and B297T cell lines in comparison with WT controls (Supplementary Fig. S3 ). Picrosirius red staining of tumor sections revealed increased polarized intensity in Braf V600E / Pten À/À /TPO-Cre tumors, demonstrating higher content of mature and cross-linked collagen fibers (Fig. 4E) H340T and Hras1, suggesting that the increased motility response to Col 1 is specific to Braf and not Hras-driven thyroid tumor cells.
COL 1 and LOX are upregulated in human PTC and are associated with aggressive histologic variants of PTC and PDTC To determine whether these murine models recapitulated human disease and reflected changes observed in patients, the Oncomine database (29) was used to investigate COL1A1 and LOX expression in thyroid tumors from the Giordano cohort (30). COL1A1 and LOX expression were increased in PTC (Fig. 5A ) compared with normal thyroid, FTC, and FVPTC, which is associated almost exclusively with RAS mutations and displays many pathologic features similar to FTC (2). COL1A1 and LOX expression levels were further increased in tall-cell variant PTC, a more aggressive form of PTC, and highest in undifferentiated thyroid cancers (Fig. 5A) . The cBioPortal was used to analyze thyroid cancer data in The Cancer Genome Atlas (TCGA) dataset in order to correlate COL1A1 and LOX upregulation with mutational status. COL1A1 and LOX upregulation occurred in 8% and 10%, respectively, of all thyroid tumors analyzed (397 cases), and occur exclusively in thyroid tumors harboring BRAF, but not RAS, mutations (Fig. 5B) . Strong tendencies in the rate of cooccurrence between BRAF mutations and COL1A1 upregulation, BRAF mutations and LOX upregulation, and COL1A1 and LOX upregulation in thyroid cancers were found (Table 1) . Together, these results suggest that COL1A1 and LOX cooperate in thyroid cancer progression and that upregulation of COL1A1 and LOX occurs in response to BRAF, but not RAS, activation in thyroid cancer.
Upregulation of COL1A1 and LOX is associated with decreased overall survival in thyroid cancer patients
Mutations in BRAF correlate with decreased overall survival in thyroid cancer patients (41) . Given that upregulation of COL1A1 and LOX occurs predominantly in thyroid tumors harboring BRAF mutations, we sought to determine whether COL1A1 and LOX overexpression was associated with reduction of overall survival in thyroid cancer. Co-upregulation of COL1A1 and LOX in thyroid cancer (N ¼ 41 cases) results in a significant decrease in overall survival in thyroid cancer patients (Fig. 5D ) compared with patients with tumors without COL1A1 and LOX upregulation. These results suggest that overexpression of COL1A1 and LOX contributes to disease progression in thyroid cancer and may contribute to thyroid cancer-related mortality.
Discussion
Each of the components that make up the TME, including tumor cells, non-malignant infiltrating stromal cells, and ECM proteins, work in concert to establish a permissive niche that is essential for tumorigenesis (42) . While many studies have addressed the involvement of a singular cell type, such as fibroblasts or immune cells, or ECM component in tumor development, few studies have investigated the cross-talk between multiple components within the TME and how these complex relationships function together to promote tumor development. In this study, we dissected the cellular and non-cellular components within the TME of thyroid cancer in order to understand how interactions between these components contribute to thyroid cancer progression.
The BRAF V600E mutation is associated with a more aggressive tumor phenotype in thyroid cancer patients and has recently been implicated in the modulation of the TME through the regulation of ECM components (43) . Genes associated with ECM remodeling, including integrins, TGFb1, and fibronectin, are upregulated in PTCs with BRAF V600E mutations when compared with PTCs without the mutation (44), suggesting activation of BRAF is critical for the development of a fibrotic tumor stroma. In agreement with these findings, our data demonstrate that activation of Braf and PI3K signaling in thyrocytes results in the development of a fibrotic and reactive tumor stroma in Braf V600E /Pten À/À /TPO-Cre tumors, characterized by increased fibroblast recruitment and stromal deposition of Col 1 (Fig. 6 ). In this model, we propose that fibroblasts are recruited to the thyroid TME by Braf /TPO-Cre mice, a closely related murine model of thyroid cancer in which mice develop follicular carcinomas that progress to PDTC (A. Franco; manuscript in preparation). In addition, Col 1 had no effect on the motility of Hras-driven tumor cell lines in vitro. These data indicate that in the context of Pten loss, activation of Braf, but not Hras, results in a fibrotic response in the TME of thyroid cancer that promotes tumor progression and potentially invasion. Further supporting fibroblast recruitment to the thyroid TME is Braf V600E specific, only conditioned media from Braf V600E /Pten À/À /TPO-Cre cells was able to induce proliferation and migration of fibroblasts in vitro. These results suggest that activation of Braf, but not Hras, induces secretion of factors that promote fibroblast migration and likely leads to the increased fibroblast recruitment observed in vivo. Interestingly, RAS activation is associated with increased inflammation and tumor immune cell infiltration in murine models of lung and pancreatic ductal adenocarcinoma (45, 46) , and mutant BRAF V600E induces fibroblast activation in melanoma cell lines (47) . Future studies are needed to unravel the molecular mechanisms by which the activation of closely related MAPK effectors, like RAS and RAF, lead to the development of distinct TMEs through the differential recruitment of various cell types or ECM remodeling.
The biomechanical properties of a tumor-associated matrix can have a strong influence on cellular behavior (48) . LOX is a known driver of ECM stiffness within the TME due to its ability to crosslink collagen fibers, and inhibition of LOX attenuates metastasis in mouse models of breast cancer and, more recently, thyroid cancer (39, 40, 49) . Increased matrix stiffness also induces the activation of integrin signaling and downstream ERK activation and promotes the stabilization of focal adhesion complexes that can drive malignancy (50) . Braf Advanced forms of thyroid cancer are associated with mutations in the MAPK pathway and additional mutations that result in constitutive PI3K activation (33) . These data demonstrate that activation of Braf V600E and PI3K leads to the development of PTCs that rapidly progress to PDTCs. These tumors are associated with a fibrotic TME characterized by increased stromal collagen deposition and Lox upregulation. These murine models faithfully recapitulate patient tumors by which increased COL1A1 and LOX expression is associated with PTC compared with FTC and normal thyroid, and that COL1A1 and LOX are expressed at highest levels in PDTC and ATC. Together, these data support the critical role of these ECM components in proliferation, and activation of tumor-associated fibroblasts in the TME. Activated fibroblasts synthesize and deposit collagen fibrils in the TME. Braf V600E / Pten hom tumor cell-derived LOX cross links fibroblastderived collagen fibrils to form mature and cross-linked collagen fibers that augment tumor cell motility, promoting thyroid cancer progression.
promoting thyroid cancer progression. COL1A1 and LOX expression in human PTCs is strongly correlated with BRAF, but not RAS mutations. RAS mutations are very common in FTC and FVPTC, while BRAF mutations are closely associated with classical PTC, suggesting that COL1A1 and LOX upregulation in thyroid cancer occurs in response to BRAF activation and may drive PTC versus FTC development. Finally, COL1A1 and LOX upregulation is associated with decreased overall survival in thyroid cancer, implicating COL1A1 and LOX as mediators of cancer progression and may serve as a prognostic indicator of disease status in addition to the BRAF V600E mutation in thyroid cancer.
While it is now widely accepted that the TME is essential for tumorigenesis, most studies only address the contribution of singular TME component to cancer progression. Considering that the TME is composed of multiple components (both cellular and non-cellular), studies that aim to investigate how these components work together to establish a niche permissive for tumorigenesis are needed to fully understand the mechanisms of tumor development and therapeutic resistance. This study is the first to identify and describe the interaction between tumor cells, fibroblasts, collagen, and Lox in the TME of thyroid tumors, providing a model by which this dynamic interaction may drive thyroid tumor progression (Fig. 6 ). We hope that these results will lead to the development of more effective therapeutic strategies for thyroid cancer that account for the complexity of the TME in vivo.
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